MDNA News and Press, Medicenna Therapeutics Corp. From 08/01/23

2023-08-01 15:49:41 ET Summary MDNA failed to report data from the fifth dosing cohort, of its phase 1/2 ABILITY study of MDNA11, in Q2'23 as expected. The company is instead presenting data from both the fifth and sixth cohorts of the trial on August 9, 2023. MDNA has cash to...

Medicenna Therapeutics Corp. has been granted U.S. Patent No. 11,680,090 titled “Interleukin-2 Fusion Proteins and Uses Thereof.” The patent covers a method for enhancing immune cell survival and proliferation or inhibiting cell death and therefore improving fitness of cancer fi...

2023-07-28 15:05:28 ET Medicenna Therapeutics press release ( NASDAQ: MDNA ): Q1 GAAP EPS of -$0.04. For further details see: Medicenna Therapeutics GAAP EPS of -$0.04

Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined dose-limiting toxicities MDNA11 clinical update scheduled for August 9; conference call to discuss data from cohorts five and six, recom...

Medicenna's President and CEO, Dr. Fahar Merchant, was invited to participate and present at the Brain Cancer Research Roundtable organized by the National Brain Tumor Society (“NBTS”) The focus of the event was to explore ways to expedite development of novel therapie...

2023-06-27 16:08:56 ET Medicenna Therapeutics press release ( NASDAQ: MDNA ): FY GAAP EPS of -$0.16 in-line. As of March 31, 2023, cash and cash equivalents were $33.6 million, compared to $20.5 million on March 31, 2022. These funds are expected to provide the Company wit...

MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response continuing for over 40 weeks and stable disease for over 70 weeks as a third-line treatment in a patient with metastatic melanoma MDNA11 clinical update is anti...

2023-04-27 07:59:01 ET Clinical stage immuno-oncology company, Medicenna Therapeutics ( NASDAQ: MDNA ) received a notice from the Nasdaq granting the request for a 180-day extension to regain compliance with the minimum bid price requirement of $1 per share. The compa...

TORONTO and HOUSTON, April 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on April 25, 2023 it received a notice (the “Extension Notice”) from th...

TORONTO and HOUSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will participa...